Compare Moderna, Inc. (MRNA) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Upwork Inc — how do they compare? Moderna, Inc. trades at $136.21 (market cap $54.14B), while Upwork Inc trades at $8.24 (market cap $1.03B). The key difference: Moderna, Inc. is far larger — about 52.6× Upwork Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | UPWK | |
|---|---|---|
Market Cap | $54.14B | $1.03B |
Sector | Health | Industrials |
52-Week High | $174.38 | $22.11 |
52-Week Low | $22.36 | $7.84 |
Enterprise Value | $50.29B | $791.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Upwork (UPWK) trades at $8.32, down 5.35% amid bearish technical signals and recent earnings volatility. The stock shows mixed fundamentals with strong gross margins of 77.21% but declining net income margins from 28.02% in 2024 to 14.65% in 2025. Recent Q2 2026 earnings beat expectations but weak guidance triggered a selloff. Analyst consensus remains positive with a $9.00 price target despite ongoing securities fraud investigations.
The stock presents a value opportunity with low P/E of 10.67 and P/S of 1.44, but faces significant headwinds from AI disruption to freelance demand and multiple legal investigations. Near-term performance depends on management's ability to navigate AI transition while maintaining client growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
